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Abstract
Objectives: Bladder cancer (BCA) is a worldwide disease and shows a wide range of geographical variation.
The aim of this study is to analyze the prevalence of schistosomal and non-schistosomal associated BCA
as well as compare our findings with the 2004 WHO consensus classification of urothelial neoplasms and
with other publications.
Patients and methods: The archival materials of 180 urinary bladder specimens were collected from Depart-
ment of Pathology, King Abdul-Aziz University Hospital (KAUH), Jeddah, Western region, Saudi Arabia.
The regional prevalence of this cancer was identified and studied, and a comparison between schistoso-
mal and non-schistosomal associated BCA was made. Additionally, the study revised and classified these
neoplasms according to the most recent 2004 WHO classification of urothelial neoplasms. The type of
mural invasion either muscularis mucosae (MM) or muscularis propria (MP), other associated lesions as
carcinoma in situ (CIS) as well as, metaplasia and schistosomal infestation were assessed.
Results: Urothelial cell neoplasms (UCN) comprised 161 cases (89.4%), squamous cell carcinoma (SCC)
represented 12 cases (6.7%), adenocarcinoma 5 cases (2.8%), and sarcomatoid carcinoma detected in 2
cases (1.1%). Among all these cases schistosomal associated BCA represented 13 cases (7.2%), while
8%) were non-schistosomal associated BCA. In the former category, 11
cell carcinoma and 2 (1.1%) urothelial cell carcinoma (UCC) whereas,the remaining 167 cases (92.
cases (6.1%) were squamous∗ Corresponding author at: Department of Pathology, Faculty of Medicine,
eni-suef and Northern Borders Universities, P.O. Box 3121, Arar 91413,
audi Arabia.
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non-schistosomal associated cancer that included UCN, SCC, adenocarcinoma, and sarcomatoid carcinoma
found in 159, one case, 5, and 2 cases. Invasion of muscularis propria was detected in 30 cases (16.7%) and
muscularis mucosae invasion in 45 cases (25%).
Conclusion: According to WHO classification of urothelial neoplasms accurate categorization of BCA is
very important for both diagnostic and therapeutic values.
© 2012 Production and hosting by Elsevier B.V. on behalf of Pan African Urological Surgeons’ Association.
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Then all the stained slides examined by two consultant pathologists
for the evidence of BCA. Afterward the detected BCA in our study
categorized according to the 2004 WHO consensus classification
for urothelial neoplasms [34] (Table 1).
Table 1 Categorization of urothelial neoplasms according to the
2004 WHO classification.
PUNLMP Low rate of recurrencea, low rate of grade
and stage progressionb
PUC, LG Higher recurrence rate than PUNLMPa,
stage as PUNLMP, grade lower than PUC,
HG
PUC, HG Have a significant risk of recurrence and
progressiona
PUNLMP: papillary urothelial neoplasm of low malignant potential;
PUC, LG: papillary urothelial carcinoma, low grade; PUC, HG: papillary
ND licIntroduction
An estimated 68,810 new cases of BCA were diagnosed in the
United States in the year 2008 and 14,100 deaths from it were
estimated for the same year [1]. This tumor affects one in 4000
people and accounts 5% of all diagnosed cancers in human [2]. The
incidence of this cancer varies worldwide that is highest in North
America and Europe [3]. In spite of earlier diagnosis and better care,
the incidence is still rising [4,5]. Due to its prevalence, morbidity
and mortality previous studies investigated the strong association
between schistosomiasis and smoking in the development of BCA
[6–13].
Additionally workers in automobile industry, leather and apparel
and petrochemical industries are associating with increased risk of
BCA [14–17]. The manifestations of BCA are in the form of hema-
turia, irritative symptoms, constipation, fecal incontinence, back
pain, and renal failure [18,19]. Schistosomal-associated BCA has
distinctive clinicopathological features quite different from other
regions worldwide. This tumor affects patients at a much younger
age with male predilection [20–23]. In Egyptian patients SCC is the
most common histological type and representing 76.6%. Since, it
arises on top of squamous metaplasia which resulting from chronic
bilharzial cystitis [21]. Previous studies were mentioned in spite
that squamous cell carcinoma is the commonest histological type of
BCA its percentage is in decline as with the strategy toward erad-
ication of schistosomiasis [24,25]. Associated with these studies
and others, the pattern of histopathology of BCA showed marked
change, where SCC constituted less than 60% [26–28]. In Egyptian
patients BCA ranks first in males representing 16.2% of male can-
cer [25,29]. Whereas, in Saudi patients and according to the tumor
registry, BCA ranks the 10th among males and the 20th among
females. The majority of this malignancy is conventional urothelial
cell carcinoma [30].
Histologically BCA is including conventional UCC, squamous cell
carcinoma, adenocarcinoma and small cell carcinoma. Urothelial
cell carcinoma may be further subdivided into an additional 14 sepa-
rate subtypes [31,32]. The World Health Organization/International
Society of Urological Pathology (WHO/ISUP) described in the
classification of urinary bladder tumors; mesenchymal neoplasms,
lymphomas, and germ cell neoplasms [33]. As well as, 2004 WHO
categorized non-invasive urothelial neoplasms into papillary urothe-
lial neoplasm of low malignant potential (PUNLMP), low and high
grades papillary urothelial carcinoma (PUC), and papilloma [34].
The diagnosis of UCC is compounded by the need for accurate
pathologic staging. The identification of muscularis propria inva-
Open access under CC BY-NC-sion is the most critical challenges in this theme [35–37]. Accurate
recognition of muscularis propria invasion is crucial as it is the crit-
ical crossroad between conservative and aggressive management of
these patients [38]. This pattern of invasion is sometimes difficultnd challenging particularly when inconsistent layers of muscu-
aris mucosae were seen as hyperplastic bundles of muscles and
imic the muscles of muscularis propria. In this condition the tumor
taging may be difficult particularly in unoriented specimens as
ystoscopic biopsies or transurethral resection specimens [39–41].
ubjects and methods
etting and specimens
he material of the present study included 180 cases of urinary
ladder specimens. These cases were seen and collected from the
epartment of Pathology, KAAUH, Jeddah, through the period,
anuary 1995–April 2008.
he clinical data included the age, gender, clinical presentation, cys-
oscopical and radiological findings obtained from the patients files.
ll the patients were seen and examined clinically in the urology
utpatient clinics, KAAUH.
istopathological examination and interpretation
ll the specimens received were fixed in 10% neutral buffered
ormalin solution. According to the type of the received material,
URB were weighed and measured, respectively, and then totally
ubmitted. All the fragments of endoscopic biopsies were processed
n many cassettes. The radical cystectomy specimens were weighed,
nked, measured and processed in different cassettes. Five micron
ections were taken and stained by hematoxylin and eosin (H&E).
ense.urothelial carcinoma, high grade.
Refs. [42,44].
a Ref. [43].
b Ref. [45].
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Table 3 The comparison between papillary urothelial cell neo-
plasm and squamous cell carcinoma in all cases studied.
PUC SCC Total
146 (81.1%) 12 (6.7%) 180
PUC: papillary urothelial cell carcinoma; SCC: squamous cell carci-
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s well as, all the cases were examined for mural invasion and for
ny calcified schistosomal ova. The specimens were investigated
or other associated bladder lesions as such carcinoma in situ and
etaplastic lesions.
tatistical analysis
he statistical analysis was performed using SPSS computer soft-
are (SPSS version 16 Microsoft windows). Z test was used for the
omparison between two proportions. Results were considered to
e statistically significant at p < 0.05.
esults
linical findings of all cases studied
he age of our patients ranged from 26 to 86 years with a mean of
5.3 years and regarding gender, there were 150 cases (83.3%) males
nd 30 cases (16.7%) females. All patients came to the urologic out-
atient clinics at KAUH. The majority of them were complained of
ower urinary tract symptoms that ranged from burning micturi-
ion to gross hematuria. After detailed clinical examination, the
ncluded cases were diagnosed as query BCA. Then all cases were
nvestigated radiographically (plain X-ray, intravenous excretory
rography and abdominal ultrasound), and laboratory investigations
or clinical fitness aiming to suitable surgical procedures were per-
ormed. Afterward these cases underwent endoscopical examination
here biopsies were taken.
istopathological findings of all cases studied
he received specimens formed of 15 cases (8.3%) radical cys-
ectomies, 20 cases (11.1%) TURB and the remaining 145 cases
80.6%) were cystoscopical biopsies. In this study the major-
ty of the cases were urothelial neoplasms, which represented
61 (89.4%) whereas, the non-urothelial neoplasms which includ-
ng squamous cell carcinoma, adenocarcinoma and sarcomatoid
arcinoma were seen in 19 cases (10.6%) with P value < 0.001
hat was highly significant. Among urothelial neoplasms, 15
ases (8.3%) were papillary urothelial neoplasm of low malig-
ant potential (PUNLMP), low grade papillary urothelial carcinoma
ncompassed 95 cases (52.8%), and the high grade one was
epresented 51 cases (28.3%). In the same way, the first two
ypes of non-urothelial neoplasms were included 12 cases (6.7%)
quamous cell carcinoma and 5 (2.8%) cases adenocarcinoma.
he relationship between these two variants was insignificant
ith P value 0.09. The third variant of non-urothelial neo-
lasms was sarcomatoid carcinoma that included 2 cases (1.1%)
Table 2).
h
1
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Table 2 Histological classification of BCA in all cases studied.
Histological categories
Urothelial cell neoplasms Non-u
PUNLMP PUC SCC
LG HG
15 95 51 12
PUNLMP: papillary urothelial neoplasm of low malignant potential; PUC, LG:
carcinoma, high grade; SCC: squamous cell carcinoma; Adeno.: adenocarcinomnoma.
egarding, the comparison between the main two histopatholog-
cal types of BCA in this study that were papillary urothelial
arcinoma and squamous cell carcinoma. The former was
he most predominant that was followed by the later one
hich represented a lower prevalence. The relationship between
hem was significant with P value < 0.001 (Table 3). In the
ame theme, adenocarcinoma and sarcomatoid carcinoma were
ncommon tumors affecting the urinary bladder among these
atients.
hirteen (7.2%) out of 180 cases showed calcified bilharzial
va in the tumor tissue. Among them 11 cases (6.1%) were
quamous cell carcinoma, while the remaining 2 (1.1%) were
apillary urothelial carcinoma. In the opposite direction, the remain-
ng 167 cases (92.8%) were free from schistosomal ova. So, in
his region schistosomal associated BCA showed a minor preva-
ence in comparison to non-schistosomal associated cancer. The
elationship between these two groups of urinary bladder can-
ers was highly significant with P value < 0.001. This finding
ay explain that there are other risk factors may be linked to
he pathogenesis of BCA while, schistosomiasis implicated in a
inor degree in the occurrence of this tumor among this location
Table 4).
egarding malignant invasion 30 (16.7%) out of 180 cases
evealed muscularis propria invasion and 45 cases (25%%) had
nfiltration within the muscularis mucosae. in the opposite way,
he remaining 105 cases (58.3%) were free from tumor inva-
ion. The relationship between invasive and non-invasive types
f BCA was significant with P value is 0.01. Surprisingly, all
he cases of squamous cell carcinoma regarding its differentia-
ion showed invasion in either muscularis propria or muscularis
ucosae. Additionally 10 out of 180 cases (5.6%) were asso-
iated with carcinoma in situ, while the remaining 170 cases
94.4%) were free. The relationship between these two categories
f BCA that included carcinoma in situ and the free one was
ighly significant with P value < 0.001. For metaplastic changes
0 out of 180 cases (5.6%) showed squamous metaplasia, while 6
3.3%) revealed glandular metaplasia of the covering urothelium
Table 5).
Total
rothelial cell neoplasms
Adeno. S Ca
5 2 180
papillary urothelial carcinoma, low grade; PUC, HG: papillary urothelial
a; S Ca: sarcomatoid carcinoma.
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Table 4 Relationship between schistosomiasis and BCA in all cases studied.
Bladder cancer Total
Schistosomal-associated Non-schistosomal-associated
SCC PUC Total UCN SCC Adeno. S Ca Total
11
(6.1%)
2
(1.1%)
13
(7.2%)
159
(88.3%)
1
(0.6%)
5
(2.8%)
2
(1.1%)
167
(92.8%)
180
(100%)
SCC: squamous cell carcinoma; PUC: papillary urothelial cell carcinoma; UCN: urothelial cell neoplasm; Adeno.: adenocarcinoma; S Ca: sarcomatoid
carcinoma.
Table 5 Invasion of BCA and other associated lesions in all cases studied.
Invasion Associated lesions Total
MP MM CIS Metaplasia
30 45 10 Squamous Glandular 180
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MP: muscularis propria; MM: muscularis mucosae; CIS: carcinoma in sit
Discussion
The incidence of BCA is increasing, estimated to be the ninth most
common cancer worldwide and the 13th cause of cancer related
death [46]. Also, this cancer is the 5th most commonly diagnosed
non-cutaneous solid malignancy [47,48].
The age of our patients was ranged from 26 to 86 years with a mean
55.3 also, 150 cases (83.3%) were males, and the other 30 (16.7%)
were females. These findings are in agreement with [25,49] other
studies from the Middle East where the mean age of their cases were
56 and 58 years. Additionally, these authors noted that these ages
were less than reported in the literatures of other parts in the world.
As well as in schistosoma free countries throughout the world the
highest incidence of BCA is in the sixth or seventh decades of life
with a peak between 65 and 72 years [50,51]. Our findings do not
agree with what others mentioned in certain regions, such as Egypt,
Sudan and Iraq as the mean age of the highest incidence is between
40 and 49 years [21,52,53]. In this study the gender ratio was 5:1 that
does not equal to a higher one in endemic areas such as Egypt which
is 3:1 [54]. In Jordan a study reported the highest incidence between
40 and 59 years with a percentage 35.9% [55]. In Saudi Arabia
BCA affects 2.8/100,000 in Makkah region, which is the place of
this study. In contrast the highest incidence of BCA in Saudi Arabia
was in Tabuk region which was 5.5/100,000. While, in Northern
and Eastern regions the incidence was between 4.5/100,000 and
2.6/100,000 [56].
In the current study, 15 cases (8.3%) were papillary urothelial
neoplasm of low malignant potential, 95 (52.8%) low grade pap-
illary urothelial carcinoma and 51 (28.3%) high grade papillary
urothelial carcinoma, 12 (6.7%) squamous cell carcinoma, 5 (2.8%)
adenocarcinoma, and sarcomatoid carcinoma detected in 2 cases
(1.1%). Additionally, schistosomal associated BCA comprised 13
cases (7.2%), among them 11 (6.1%) were squamous cell carci-
noma and the remaining 2 (1.1%) were papillary urothelial cell
carcinoma. In the opposite side the remaining 167 cases (92.8%)
were non-schistosomal associated BCA. Our results are compara-
ble with those reported in KFSH & RC among 175 cases of radical
cystectomies, 56% was diagnosed as papillary urothelial cell car-
cinoma, 34% squamous cell carcinoma, and 5% adenocarcinoma.
Among these cases schistosomal associated BCA was 17% majority
t
B
p
t10 (5.6%) 6 (3.3%) (100%)
f them were squamous cell carcinoma whereas, non-schistosomal
ssociated BCA was 83% [30]. In the same manner other findings
iscussed urothelial tumors seen in 93%, SCC in 2.7%, and adeno-
arcinoma in 1.4% [57]. Also, our results were in agreement with a
tudy done on Turkish patients and reported UCC found in 77.2%,
on-schistosomal SCC in 8.9%, adenocarcinoma in 1.9% and sar-
omatoid carcinoma in 0.8% [58]. As well as in Saudi Arabia and
ccording to the Cancer Incidence Report (2004) the majority of
CA was urothelial cell carcinoma, NOS which was represented
1.8%, papillary urothelial cell carcinoma was 32.4%, squamous
ell carcinoma encompassed 9% and adenocarcinoma 1.5% of all
egistered cases. In Japan urothelial cell carcinoma was detected in
2. 1%, squamous cell carcinoma in 3.4%, and adenocarcinoma in
% [59]. In the current study squamous cell carcinoma represented
.7% out of all cases. This is not in parallel with a study performed
n Cleveland clinic from the period 1981 to 2006 which found pure
quamous cell carcinoma in 2% of cases [60]. As well as a similar
ange in other institution was reported [61]. In the same manner
ur results were in agreement with those mentioned in industri-
lized Western countries as urothelial cell carcinoma was seen in
0–95%, squamous cell carcinoma in 3–7% and adenocarcinoma
n 1–2% [62]. Additionally schistosomal associated squamous cell
arcinoma reported in 15% of cases in the developing countries
63]. A study done in Egypt during the years 1970–2007 revealed a
ignificant decline in the frequency of BCA from 27.6% to 11.7%,
rothelial cell carcinoma showed significant rise from 16% to 65.8%
nd a significant drop of squamous cell carcinoma from 75.9%
o 28.4%. They linked these changes to the decline in squamous
etaplasia of the urothelium as a result of decline in schistosomal
nfection [24]. The discrepancy between our findings and others may
e explained by incrimination of many other risk factors in the occur-
ence of squamous metaplastic changes in the urothelium in these
ndemic regions. Also, the decline of squamous cell carcinoma in
his study may be linked to lower prevalence of squamous metapla-
ia (5.6%). This explanation may be supported by previous findings
eported and linked the increased BCA risk in Egyptian patients to
ther risk factors as tobacco smoking or other occupations [55,64].
lso, several investigators mentioned smoking and other occupa-ional exposure are carcinogens of biggest risk factors to develop
CA. So, reduction of occupational carcinogens is the preventative
rograms of BCA with reduction of mortality and morbidity and
otal cost therapy of this tumor [16,65,66].
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[22
hirty (16.7%) out of all cases showed tumor invasion in muscu-
aris propria and 45 cases (25%) revealed invasion in muscularis
ucosae. All the cases of squamous cell carcinoma showed invasion
o muscularis propria. In the opposite side the remaining 105 cases
58.3%) were free from tumor deposits. Additionally 10 (5.4%) out
f all the cases revealed an associated carcinoma in situ, squamous
etaplasia was detected in 10 (5.6%), and glandular metaplasia in 6
ases (3.3%). These findings are in agreement with other studies that
entioned majority of patients with squamous cell carcinoma who
nderwent for partial or radical cystectomies demonstrated invasion
n the perivesical fat (pT3) and beyond [67,68]. A study explained
resence or absence of muscularis propria invasion is the crossroad
f radical versus conservative management of patients with BCA
40]. As well as previous researches reported in 22% of cases, the
eeply situated compact hyperplastic muscularis mucosae muscle
undles may have similarity to muscularis propria and confused
ith the later in TURB and may leading to upstaging [40,69,70].
onclusion
ladder cancer shows a wide range of geographical variation.
lso, according to the WHO classification of urothelial neoplasms,
ccurate diagnosis and categorization of BCA are mandatory, as
UNLMP group carry low rate of recurrence and progression to
nvasive cancer, low grade urothelial cell carcinoma also carries the
ame previous feature with slight increase, whereas the high grade
rothelial cell carcinoma is characterized by more rate of recurrence
nd malignant features so, of need to special therapeutic attention.
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